Clay Siegall, the Man behind the New Face of Cancer Treatment

Posted by SS Admin on September 24, 2017 in Uncategorized |

In his official Blog as the Chief executive of Seattle Genetics, Clay Siegall takes his time to highlight some of the developments in the world of Science that depicts the brilliant works of their developers and other interesting stories from all scopes of life. Recently, he posted the narration by Paul Knoepfler who was looking at some of the likely unintended outcomes of the Human Gene editing procedures. He also managed to pick a leaf of Juan Enriquez story talking about the possible turn of events that would be experienced if the future of evolution was left in the control of human beings.

Clay Siegall is the founder of Seattle Genetics, a company, which he started to improve the lives of those living with cancer. He thought of making the treatment of cancer better as it was dominated by chemotherapies that were incapable of differentiating between the killing and the healthy cells. The foundation of the Seattle Genetics was based on his passion for helping patients and the fast developments made in the research in the scientific foundation

Under his leadership at Seattle Genetics, the company gained a leadership position within the scope of anti-drug conjugates (ADCs) as well as diversifying the proprietary anti-drug conjugates for cancer treatment. Seattle Genetics, therefore, plays the role of tasking the passionate innovators in its team to dedicate their time and energy to all the activities of the company, which is all geared towards improving cancer treatment methods. The methods that were used in the treatment of cancer before the inception of Seattle Genetics left some of the needs of treatment of cancer unmet.

Clay Siegall studied Bachelor of Science in Zoology in his undergraduate level at the University of Maryland before proceeding to pursue his philosophy of doctorate in Genetics at The George Washington University. Clay gained his experience by working at a National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute. Moreover, he is a member the board of other companies. For instance, he is the Director of Ultragenyx pharmaceutical, Director at Washington Roundtable as well as Alder BioPharmaceuticals which also have a significant impact on the development activities of making the cancer patients comfortable.

Leave a Reply

Copyright © 2014-2019 SpoutServer All rights reserved.
This site is using the Desk Mess Mirrored theme, v2.2.4.1, from BuyNowShop.com.